MX2019006189A - Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. - Google Patents

Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.

Info

Publication number
MX2019006189A
MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A
Authority
MX
Mexico
Prior art keywords
peptide
drug
hormone receptor
parathyroid hormone
targeting
Prior art date
Application number
MX2019006189A
Other languages
English (en)
Spanish (es)
Inventor
S Low Philip
A Low Stewart
Jay Howard Nielsen Jeffery
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of MX2019006189A publication Critical patent/MX2019006189A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019006189A 2016-11-30 2017-11-30 Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. MX2019006189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428492P 2016-11-30 2016-11-30
US201762553313P 2017-09-01 2017-09-01
PCT/US2017/064081 WO2018102616A1 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Publications (1)

Publication Number Publication Date
MX2019006189A true MX2019006189A (es) 2019-11-18

Family

ID=62241919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006189A MX2019006189A (es) 2016-11-30 2017-11-30 Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.

Country Status (10)

Country Link
US (3) US20200317745A1 (enExample)
EP (1) EP3548012A4 (enExample)
JP (2) JP7649624B2 (enExample)
CN (1) CN110114065A (enExample)
AU (1) AU2017367699B2 (enExample)
BR (1) BR112019011070A2 (enExample)
CA (1) CA3045458A1 (enExample)
IL (1) IL266977B2 (enExample)
MX (1) MX2019006189A (enExample)
WO (1) WO2018102616A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
EP3796941A4 (en) * 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110551201B (zh) * 2019-08-26 2020-04-28 杭州彗搏科技有限公司 一种新型骨形成蛋白2来源的环肽、制备方法及其应用
CN114364327A (zh) * 2019-09-12 2022-04-15 雷迪厄斯健康公司 用阿巴帕肽改善脊柱融合的方法
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
JP2023547889A (ja) * 2020-10-26 2023-11-14 パーデュー・リサーチ・ファウンデーション 脊椎融合を治療するための化合物、組成物、および使用の方法
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
WO2023136866A1 (en) * 2022-01-14 2023-07-20 Novosteo Llc Bone targeted treatment in osteogenesis imperfecta
WO2024246840A1 (en) * 2023-06-01 2024-12-05 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities
WO2025019691A1 (en) * 2023-07-19 2025-01-23 Zymeron Corporation Drug conjugates for bone marrow protection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
EP1950224A3 (en) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
WO2004062588A2 (en) * 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス,インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
DK2155874T3 (en) * 2007-04-09 2016-08-01 Univ Arkansas FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
PL2158319T4 (pl) * 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
WO2009141823A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
CN102824647B (zh) * 2011-06-13 2014-07-23 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
WO2014033540A2 (en) * 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
EP3016674A4 (en) 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
EP4137147A3 (en) * 2015-03-03 2023-04-05 Radius Health, Inc. Uses of abaloparatide in reducing fracture risk
WO2016196400A1 (en) * 2015-05-29 2016-12-08 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CN106039316B (zh) * 2016-05-03 2019-04-02 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Also Published As

Publication number Publication date
US20210283227A1 (en) 2021-09-16
CA3045458A1 (en) 2018-06-07
RU2019119701A (ru) 2021-01-14
AU2017367699A1 (en) 2019-07-11
AU2017367699B2 (en) 2023-12-07
JP2020500871A (ja) 2020-01-16
RU2019119701A3 (enExample) 2021-02-16
BR112019011070A2 (pt) 2019-10-01
US20200316174A1 (en) 2020-10-08
EP3548012A4 (en) 2020-07-22
WO2018102616A1 (en) 2018-06-07
EP3548012A1 (en) 2019-10-09
JP2023029957A (ja) 2023-03-07
IL266977B1 (en) 2023-09-01
IL266977A (en) 2019-07-31
IL266977B2 (en) 2024-01-01
US10960054B2 (en) 2021-03-30
JP7649624B2 (ja) 2025-03-21
US20200317745A1 (en) 2020-10-08
CN110114065A (zh) 2019-08-09
AU2017367699A8 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2019006189A (es) Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.
IN2015DN03219A (enExample)
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
MX350378B (es) Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
HK1211483A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2018014279A (es) Tratamiento terapeutico de cancer de mama con base en estado de c-maf.
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
MX2019013857A (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
NZ721835A (en) An osseointegrable device
EA201691567A1 (ru) Способы лечения легких травм головного мозга
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
MX2017016418A (es) Composiciones de liraglutida de acción prolongada.
BR112017002878A2 (pt) distribuição coordenada de tratamento de copd
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
EP3626712A3 (en) Liver x receptor (lxr) modulators
WO2020086479A9 (en) Dosing
WO2016026917A3 (en) Medicament and apparatus for treating chronic kidney disease
SG11201808253YA (en) Marker for predicting treatment response to anti-cancer agent in solid cancer patients
MX380088B (es) Uso terapéutico de una solución oftálmica acuosa estéril.
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
Avci Ibandronic acid
EP3159003A3 (en) Composition for enhancing bone growth, preventing bone resorption disorders and for joint health